Neurocrine Biosciences (NBIX) Receivables - Net (2010 - 2026)
Neurocrine Biosciences' Receivables - Net was $887 million in Q2 2026, up 48.9% from $595.7 million a year earlier and up 15.5% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Receivables - Net (2010 - 2026) Analysis & Trends
At the end of FY2025, Receivables - Net at Neurocrine Biosciences came in at $686.8 million, up 43.4% from FY2024.
- Receivables - Net has now increased for eight consecutive years, with a five-year compound annual growth rate of 34.3% (FY2020 to FY2025).
- In earlier years, Receivables - Net was $479.1 million in FY2024 (+9.1%), $439.3 million in FY2023 (+25.5%), $350 million in FY2022 (+88.7%) and $185.5 million in FY2021 (+18.1%).
- The Q2 2026 figure marks the highest quarterly Receivables - Net in data going back to Q4 2010.
- Compared with a year earlier, Receivables - Net has increased for 21 straight quarters, with growth averaging 32.3% over the last eight quarters.
- Over the past five years, the year-over-year growth in Receivables - Net ranged from 4.4% (Q3 2021) to 88.7% (Q4 2022).
- Per Business Quant data, NBIX's Receivables - Net in the three quarters before Q2 2026 was $768.1 million (Q1 2026), $686.8 million (Q4 2025) and $728 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn |
| 10 | Neurocrine Biosciences | 14.29 Bn | 9.99 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 887.00 Mn |
| Mar 31, 2026 | 768.10 Mn |
| Dec 31, 2025 | 686.80 Mn |
| Sep 30, 2025 | 728.00 Mn |
| Jun 30, 2025 | 595.70 Mn |
| Mar 31, 2025 | 516.00 Mn |
| Dec 31, 2024 | 479.10 Mn |
| Sep 30, 2024 | 481.10 Mn |
| Jun 30, 2024 | 468.20 Mn |
| Mar 31, 2024 | 450.70 Mn |
| Dec 31, 2023 | 439.30 Mn |
| Sep 30, 2023 | 417.80 Mn |
| Jun 30, 2023 | 387.60 Mn |
| Mar 31, 2023 | 391.60 Mn |
| Dec 31, 2022 | 350.00 Mn |
| Sep 30, 2022 | 301.20 Mn |
| Jun 30, 2022 | 279.00 Mn |
| Mar 31, 2022 | 263.50 Mn |
| Dec 31, 2021 | 185.50 Mn |
| Sep 30, 2021 | 163.80 Mn |
API Access
Neurocrine Biosciences Receivables - Net API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables-net&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables-net", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables-net&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();